Department of Orthopaedic Surgery, Nagoya University Graduate School of Medicine, Nagoya, Japan.
Department of Orthopaedic Surgery, Aichiika Medical Center, Okazaki, Japan.
Nagoya J Med Sci. 2024 May;86(2):314-325. doi: 10.18999/nagjms.86.2.314.
Advanced glycation end products (AGEs) have been reported to be associated with osteoporosis, aging, sarcopenia, and frailty. This study aimed to investigate the association AGEs with locomotive syndrome (LS). Participants were Japanese individuals aged 39 years or older who participated in the Yakumo Study (n=230). AGEs were measured by skin autofluorescence (SAF) using an AGE reader. We investigated SAF values for each locomotive stage. Multivariate logistic regression models were used to calculate the odds ratios of LS-associated factors. The relationships between SAF and physical performance and bone mineral density (BMD) were investigated. A receiver operating characteristic (ROC) curves were generated to determine the optimal cut-off value of SAF for predicting LS. SAF values tended to increase correspondingly with LS severity. SAF was an independently explanatory factor for LS (odds ratio 2.70; 95% confidence interval [CI] 1.040-6.990). SAF was positively correlated with the 10-m walking speed, The Timed Up and Go test results, and was negatively correlated with BMD. ROC curve represented by SAF for the presence or absence of LS risk had an area under the curve of 0.648 (95% CI: 0.571-0.726). High SAF values were identified as an independent risk factor for LS. AGEs could be a potential screening tool for people for LS.
晚期糖基化终产物(AGEs)与骨质疏松症、衰老、肌肉减少症和虚弱有关。本研究旨在探讨 AGEs 与行动障碍综合征(LS)的关系。参与者为参加薮下研究(n=230)的年龄在 39 岁及以上的日本个体。通过 AGE 阅读器用皮肤自发荧光(SAF)来测量 AGEs。我们研究了每个行动阶段的 SAF 值。使用多变量逻辑回归模型计算与 LS 相关因素的比值比。研究了 SAF 与身体表现和骨矿物质密度(BMD)之间的关系。生成了受试者工作特征(ROC)曲线,以确定 SAF 预测 LS 的最佳截断值。SAF 值随着 LS 严重程度的增加而相应增加。SAF 是 LS 的独立解释因素(比值比 2.70;95%置信区间[CI]1.040-6.990)。SAF 与 10 米步行速度、计时起立行走测试结果呈正相关,与 BMD 呈负相关。以 SAF 表示 LS 风险存在或不存在的 ROC 曲线的曲线下面积为 0.648(95%CI:0.571-0.726)。高 SAF 值被确定为 LS 的独立危险因素。AGEs 可能是 LS 患者的潜在筛查工具。
Geriatr Gerontol Int. 2024-6
J Clin Endocrinol Metab. 2022-1-18
Diabetes Metab Res Rev. 2024-2
Minerva Endocrinol (Torino). 2023-6-16
BMC Musculoskelet Disord. 2022-8-11
J Clin Endocrinol Metab. 2022-1-18